Latest Period
Q1 2026
Security Snapshot
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) Institutional Ownership
CUSIP: 22978P106
13F Institutional Holders and Ownership History from Q1 2018 to Q1 2026
Institutions Reporting
52
Shares (Excl. Options)
21,301,307
Price
$0.23
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- CUE on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 21,301,307
- Total 13F value
- $4,897,658
- Portfolio coverage rank
- 0%
- Share change
- -395,525
- Value change
- -$151,601
- Number of holders
- 52
- Shares outstanding
- 43,411,663
- SEC-reported price per share
- $0.67
- Insider filing price
- $0.67
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 22978P106.
- 52 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 48 to 52 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $6,659,692 to $4,897,658.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 52 institutions filings for Q1 2026.
Security key
22978P106
Latest holder period
Q1 2026
13F holders
52
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
CUE full holder history
Cue Biopharma, Inc. SEC filings
Cue Biopharma, Inc. company facts
Cue Biopharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 22978P106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
CUE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Bleichroeder LP | 10% | 0% | $5,269,789 | 6,127,662 | 0% | Bleichroeder LP | 19 Mar 2025 | |
| STROME MARK E | 5% | $1,862,968 | 2,166,242 | Mark E. Strome | 14 Nov 2022 | |||
| Slate Path Capital LP | 1.4% | $790,199 | 918,836 | Slate Path Capital LP | 31 Dec 2024 |
As of 31 Mar 2026, 52 institutional investors reported holding 21,301,307 shares of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE). This represents 49% of the company’s total 43,411,663 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
49%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Bleichroeder LP | 16% | 6,819,164 | 0% | 0.27% | $1,567,726 |
| GC Wealth Management RIA, LLC | 11% | 4,631,644 | 0% | 0.04% | $1,064,815 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.7% | 2,457,452 | 0% | 0% | $565,214 |
| Lion Point Capital, LP | 5.1% | 2,202,854 | 0% | 3% | $506,436 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5% | 1,064,690 | +33% | 0% | $244,800 |
| VANGUARD FIDUCIARY TRUST CO | 1.3% | 543,585 | 0% | 0% | $125,025 |
| Robertson Stephens Wealth Management, LLC | 1.1% | 478,500 | 0% | 0% | $110,007 |
| BlackRock, Inc. | 1% | 449,161 | -0% | 0% | $103,261 |
| Texas Capital Bank Wealth Management Services Inc | 0.92% | 397,421 | -9.8% | 0.01% | $91,367 |
| ANGELES WEALTH MANAGEMENT, LLC | 0.71% | 310,000 | 0% | 0% | $71,269 |
| ADVISORY RESEARCH INC | 0.59% | 257,225 | 0% | 0.01% | $59,136 |
| STIFEL FINANCIAL CORP | 0.57% | 246,556 | 0% | 0% | $56,683 |
| RENAISSANCE TECHNOLOGIES LLC | 0.49% | 213,828 | -10% | 0% | $49,159 |
| BANK OF AMERICA CORP /DE/ | 0.48% | 207,708 | +0.07% | 0% | $47,565 |
| STATE STREET CORP | 0.41% | 179,353 | 0% | 0% | $41,233 |
| DIADEMA PARTNERS LP | 0.3% | 131,997 | 0.01% | $30,346 | |
| NORTHERN TRUST CORP | 0.22% | 94,606 | -6.3% | 0% | $21,750 |
| UBS Group AG | 0.2% | 88,350 | +89% | 0% | $20,320 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 0.18% | 79,500 | 0% | 0% | $18,277 |
| ADVISORTRUST PARTNERS, LLC | 0.12% | 50,000 | 0% | $11,495 | |
| Virtu Financial LLC | 0.11% | 49,553 | 0% | $11,000 | |
| Sigma Planning Corp | 0.09% | 38,750 | -5.6% | 0% | $8,909 |
| GOLDMAN SACHS GROUP INC | 0.08% | 34,151 | +138% | 0% | $7,851 |
| Persistent Asset Partners Ltd | 0.08% | 33,369 | 0% | $7,672 | |
| Visionary Wealth Advisors | 0.07% | 29,285 | 0% | $6,733 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
33
Latest
Q1 2026
Rows shown
1-25 of 33
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 21,301,307 | $4,897,658 | -$151,601 | $0.23 | 52 |
| 2025 Q4 | 21,788,519 | $6,659,692 | +$1,059,340 | $0.31 | 48 |
| 2025 Q3 | 18,058,960 | $12,982,249 | +$519,709 | $0.72 | 52 |
| 2025 Q2 | 17,351,508 | $11,856,298 | +$3,983,649 | $0.68 | 46 |
| 2025 Q1 | 11,402,706 | $10,374,424 | -$452,161 | $0.91 | 49 |
| 2024 Q4 | 11,759,494 | $12,816,995 | -$1,528,241 | $1.09 | 55 |
| 2024 Q3 | 13,910,388 | $10,533,734 | -$288,922 | $0.76 | 50 |
| 2024 Q2 | 13,807,875 | $17,121,019 | -$3,730,383 | $1.24 | 72 |
| 2024 Q1 | 16,387,055 | $30,971,606 | +$2,715,659 | $1.89 | 74 |
| 2023 Q4 | 14,886,167 | $39,304,464 | +$2,537,424 | $2.64 | 80 |
| 2023 Q3 | 14,014,675 | $32,148,839 | -$634,604 | $2.30 | 75 |
| 2023 Q2 | 13,849,849 | $50,545,862 | +$6,687,288 | $3.65 | 77 |
| 2023 Q1 | 12,055,434 | $43,037,472 | -$2,540,576 | $3.57 | 62 |
| 2022 Q4 | 12,761,302 | $36,370,518 | +$155,907 | $2.85 | 60 |
| 2022 Q3 | 12,797,287 | $28,665,093 | -$2,995,285 | $2.23 | 61 |
| 2022 Q2 | 14,083,808 | $35,042,763 | -$10,988,434 | $2.49 | 68 |
| 2022 Q1 | 17,812,661 | $87,010,965 | +$4,491,451 | $4.88 | 97 |
| 2021 Q4 | 16,533,577 | $187,228,947 | -$11,058,319 | $11.31 | 88 |
| 2021 Q3 | 16,892,813 | $245,597,815 | -$23,967,610 | $14.57 | 87 |
| 2021 Q2 | 18,582,224 | $216,368,968 | -$2,774,327 | $11.65 | 89 |
| 2021 Q1 | 18,817,560 | $229,653,033 | -$6,452,286 | $12.20 | 88 |
| 2020 Q4 | 19,314,982 | $241,658,115 | -$3,019,434 | $12.51 | 94 |
| 2020 Q3 | 19,517,235 | $293,948,076 | +$49,950,366 | $15.05 | 90 |
| 2020 Q2 | 16,042,165 | $393,156,090 | +$84,955,728 | $24.51 | 99 |
| 2020 Q1 | 13,033,369 | $184,956,981 | +$36,613,314 | $14.19 | 72 |